Skip to main content
Cash
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinanceTech & Science
PredictLive136AccountSocial
MARKETSINVESTLIVE136
Product
Kalshi ProInvestMarketsIncentive programSmall business hedgingInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQPrediction marketsFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
Series Image
  1. Medicine

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?


Begins in 226 days · Jun 30, 12:00am EDT

Chance

14%

14%

56%

56%

81%

81%

2 more

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Jan 1, 2027

Odds
21% chance
Max payout
Dec 31, 2026
$0
$27,113 vol
More Science and Technology Markets

Trending Science and Technology markets

Will the U.S. confirm that aliens exist?Best AI at the end of 2026?OpenAI market share this weekGoogle market share this weekOpenRouter token usage in Nov 9–15, 2026Anthropic market share this weekDeepSeek market share this weekHow many launches will SpaceX have in November?

Science and Technology hub

All Science and Technology markets